Florian Clatot

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Florence Dalenc et al. · The Lancet Oncology · 2022 · 285 citations

Breast Oncology, Esr1 Mutation, Endocrine-related Cancer +10

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Hélène Lanic, Jérôme Kraut-Tauzia, Romain Modzelewski et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2013 · 152 citations

Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large <scp>B</scp>‐cell lymphoma treated with immunochemotherapy

Vincent Camus, Hélène Lanic, Jerome R. Kraut et al. · European Journal Of Haematology · 2014 · 133 citations

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort

Thomas Grinda, Alison Antoine, William Jacot et al. · ESMO Open · 2021 · 125 citations · Full text